



Personalized Medicine in Retinal Diseases

Guest Editor:

Dr. Henrik Faatz

1. Department of
Ophthalmology, St. Franziskus
Hospital, 48145 Münster,
Germany

2. Achim Wessing Institute for
Diagnostic Ophthalmology,
Duisburg–Essen University, 45147
Essen, Germany

Deadline for manuscript
submissions:

15 April 2025

Message from the Guest Editor

Retinal diseases are among the most common causes of irreversible blindness. In older adults, it is often the late stage of age-related macular degeneration (AMD), while in working-age individuals, diabetic retinopathy, chronic central serous chorioretinopathy, secondary neovascularizations, or a variety of genetic diseases are more frequently responsible. Since the introduction of anti-VEGF therapy, the prognosis for patients with neovascularizations has significantly improved. Especially with the development of new anti-VEGF agents, the identification of biomarkers that can enable more individualized therapy would be desirable. This also applies to patients with diabetic retinopathy and diabetic macular edema, as well as patients with secondary neovascularization, who are currently treated non-specifically with the same substances. Further identification of individual biomarkers could also improve therapy management here. This Special Issue of the Journal of Personalized Medicine aims to present outstanding research dedicated to the individualized investigation of biomarkers for disease progression or therapy response in retinal diseases.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. David Alan Rizzieri

1. Novant Health Cancer
Institute, Winston-Salem, NC
27103, USA
2. Division of Hematologic
Malignancies and Cellular
Therapy, Duke University,
Durham, NC 27710, USA

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, ‘omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

Journal Rank: JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Journal of Personalized Medicine
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/jpm
jpm@mdpi.com
[X@JPM_MDPI](https://twitter.com/JPM_MDPI)